Hold : Actualité Hold en direct - P3 | Bourse Reflex
Accueil > Tags > Hold

  • Toutes les actualités en rapport avec « Hold »

21/04 19:45 Hold - PUBLICATION OF THE FIRST ISSUE OF GENTICEL'S SHAREHOLDER NEWSLETTER

20/04 18:30 Hold - GENTICEL REPORTS ADDITIONAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

14/04 18:00 Hold - Altamir increases cash by EUR 46.6m

06/04 18:00 Hold - Disclosure of the total number of voting rights and shares composing the share capital

14/03 07:00 Hold - GENTICEL ANNOUNCES 2015 ANNUAL RESULTS AND STRATEGIC UPDATE FOR 2016

10/03 18:30 Hold - GENTICEL UPDATES ITS FINANCIAL CALENDAR FOR 2016 AND ANNOUNCES PARTICIPATION IN KEY CONFERENCES IN H1 2016

27/01 18:40 Hold - GENTICEL REPORTS INITIAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

25/01 18:00 Hold - BUSINESS UPDATE - FOURTH QUARTER 2015

11/01 08:30 Hold - GENTICEL ANNOUNCES ITS FINANCIAL CALENDAR FOR 2016

07/01 18:00 Hold - SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

07/01 07:30 Hold - GENTICEL TO EVALUATE ROCHE MOLECULAR SYSTEMS' COBAS(R) HPV TEST IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

05/01 19:00 Hold - Genticel appoints Rémi Palmantier, PhD, as Chief Scientific Officer to accelerate its development

02/12 18:00 Hold - Benedikt Timmerman resumes CEO position at Genticel

23/11 06:05 Hold - Mannai Corporation plans to acquire 51% of the Gfi Informatique's share capital and voting rights with a view to accelerating the Gfi Informatique's growth in France and abroad

03/11 10:15 Hold - MEDTECH ANNOUNCES USD 15 MILLION NOTE FINANCING

29/10 18:00 Hold - Genticel Announces First Patient Treated in U.S. Phase 1 Clinical Trial of GTL001, Company's Therapeutic Vaccine Candidate against HPV 16/18 Infections

28/10 18:45 Hold - Business Update - Third Quarter 2015

21/09 17:40 Hold - Genticel presents first half 2015 financial results, operational progress and outlook

09/09 17:50 Hold - H1 2015 results : Current operating margin: +7.8% - Group net income: +63.8% - Interim dividend: EUR 0.13

08/09 18:30 Hold - Successfully restructured and presenting half-year results close to break-even for the first time, Theolia changes its name and becomes FUTUREN